Health Economics and Outcomes Research, Pfizer Inc., Groton, CT, USA.
Leuk Res. 2013 Jan;37(1):9-13. doi: 10.1016/j.leukres.2012.09.013. Epub 2012 Oct 29.
The increased survival associated with treatments for CML emphasize the importance of understanding the HRQOL of newly diagnosed and previously treated CML patients with all phases of disease. Functional Assessment of Cancer Therapy-Leukemia results from a phase 3 and a phase 2 trial are reported for over 900 1st, 2nd, 3rd line CP, AP, and BP patients. Physical Well-being and Leukemia symptoms were worse for patients in later lines of therapy. Individuals with AP and BP CML had poorer HRQOL than individuals with CP CML. HRQOL of CML patients was predominantly consistent with the longitudinal clinical trajectory of the disease.
CML 治疗相关的生存率提高强调了了解处于疾病各阶段的初诊和既往治疗 CML 患者的 HRQOL 的重要性。报道了来自 3 期和 2 期试验的癌症治疗功能评估-白血病结果，共涉及超过 900 名 1 线、2 线、3 线 CP、AP 和 BP 患者。对于处于较后治疗线的患者，身体状况和白血病症状更差。AP 和 BP CML 患者的 HRQOL 较 CP CML 患者差。CML 患者的 HRQOL 主要与疾病的纵向临床轨迹一致。
